Do More With Reuters
Partner Services

UPDATE 4-Allergan profit rises but Botox sales lag

Wed Jul 30, 2008 11:03pm IST
 
Email | Print | | Single Page
[-] Text [+]

(Adds conference call, analyst comment, byline)

By Debra Sherman

CHICAGO, July 30 (Reuters) - Allergan Inc (AGN.N: Quote, Profile, Research) said on Wednesday second-quarter earnings rose, matching Wall Street's estimates, even as sales of Botox and other key products were lower than expected.

While total sales rose 20 percent during the quarter, some key products, like Botox -- its biggest product -- missed Street estimates.

Amit Hazan, an analyst with Oppenheimer, blamed the smaller-than-expected Botox sales on economic weakness in the United States.

"We continue to believe Street Botox estimates are too high through 2009," he wrote in a research note. "World wide facial aesthetics sales of $64.2 million did beat the Street's $59.2 million ... but we continue to view this segment with high caution due to the economy."

The Irvine, California, company said it earned $147.3 million, or 48 cents per share, compared with $138 million, or 45 cents per share, in the year-earlier period.

Excluding special charges, including legal expenses of $9 million tied to a U.S. Department of Justice investigation involving promotional practices of Botox, Allergan earned 63 cents a share. Analysts on average expected 63 cents per share, according to Reuters Estimates.

Quarterly revenue jumped 20 percent to $1.16 billion, helped by favorable foreign exchange translations.  Continued...

Russian Finance Minister Alexey Kudrin poses with his G20 colleagues and central bank leaders during the family photo at the G20 Finance Ministers meeting at a hotel in St. Andrews, Scotland. REUTERS/POOL New
Pledge to support economies

G20 financial leaders pledged to prepare strategies to end emergency support for their economies, but to keep the aid flowing until recovery was assured.  Full Article | Related Story 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

SHOWCASE

Sanjay Sinha
Balancing Act

In India, it is a tough choice between growth, managing inflation and financial stability.  Full Article 

 
Nipun Mehta
Road to Recovery

There needs to be an acceptable balance created between education and healthcare and infrastructure spend, says Nipun Mehta of SG Private Banking.   Full Article 

 
Robot Asimo

Snapshots of Honda Motor's humanoid robot Asimo  Slideshow 

 
Marketing Strategy
Marketing Strategy

Companies are now using direct marketing methods to sell their products.  Full Article 

 
Exit Plans
Exit Plans

Factbox - Stimulus exit plans for Asia-Pacific's big 5 economies  Full Article